Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.01 USD
−188.92 M USD
0.00 USD
68.44 M
About Day One Biopharmaceuticals, Inc.
Sector
CEO
Jeremy Bender
Headquarters
Brisbane
Website
Founded
2018
FIGI
BBG00V1KSN04
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DAWN is 13.72 USD — it has decreased by −2.06% in the past 24 hours. Watch Day One Biopharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Day One Biopharmaceuticals, Inc. stocks are traded under the ticker DAWN.
DAWN stock has fallen by −10.47% compared to the previous week, the month change is a −10.41% fall, over the last year Day One Biopharmaceuticals, Inc. has showed a 13.20% increase.
We've gathered analysts' opinions on Day One Biopharmaceuticals, Inc. future price: according to them, DAWN price has a max estimate of 48.00 USD and a min estimate of 28.00 USD. Watch DAWN chart and read a more detailed Day One Biopharmaceuticals, Inc. stock forecast: see what analysts think of Day One Biopharmaceuticals, Inc. and suggest that you do with its stocks.
DAWN reached its all-time high on Sep 7, 2021 with the price of 28.70 USD, and its all-time low was 5.44 USD and was reached on May 27, 2022. View more price dynamics on DAWN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DAWN stock is 4.74% volatile and has beta coefficient of 1.48. Track Day One Biopharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Day One Biopharmaceuticals, Inc. there?
Today Day One Biopharmaceuticals, Inc. has the market capitalization of 1.35 B, it has increased by 0.23% over the last week.
Yes, you can track Day One Biopharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Day One Biopharmaceuticals, Inc. is going to release the next earnings report on Mar 10, 2025. Keep track of upcoming events with our Earnings Calendar.
DAWN earnings for the last quarter are 0.38 USD per share, whereas the estimation was −0.32 USD resulting in a 220.42% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Day One Biopharmaceuticals, Inc. earnings.
Day One Biopharmaceuticals, Inc. revenue for the last quarter amounts to 93.76 M USD, despite the estimated figure of 28.48 M USD. In the next quarter, revenue is expected to reach 27.18 M USD.
DAWN net income for the last quarter is 37.04 M USD, while the quarter before that showed −4.41 M USD of net income which accounts for 940.41% change. Track more Day One Biopharmaceuticals, Inc. financial stats to get the full picture.
No, DAWN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 155.00 employees. See our rating of the largest employees — is Day One Biopharmaceuticals, Inc. on this list?
Like other stocks, DAWN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Day One Biopharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Day One Biopharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Day One Biopharmaceuticals, Inc. stock shows the sell signal. See more of Day One Biopharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.